vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVTGet Rating) in a research report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Northland Securities raised their target price on shares of vTv Therapeutics from $1.50 to $2.00 and gave the company an “outperform” rating in a report on Wednesday, August 17th.

vTv Therapeutics Stock Performance

VTVT stock opened at $0.79 on Thursday. The firm has a fifty day moving average price of $0.90 and a 200 day moving average price of $0.85. vTv Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.40. The firm has a market cap of $82.62 million, a PE ratio of -2.63 and a beta of -1.26.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VTVT. State Street Corp boosted its stake in vTv Therapeutics by 268.7% during the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock worth $155,000 after buying an additional 150,228 shares during the period. Prudential Financial Inc. purchased a new position in vTv Therapeutics during the second quarter worth $30,000. Simon Quick Advisors LLC bought a new stake in shares of vTv Therapeutics during the second quarter worth $36,000. Finally, Millennium Management LLC lifted its position in shares of vTv Therapeutics by 12.0% during the second quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 14,845 shares during the last quarter. 7.35% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

(Get Rating)

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

See Also

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.